公开(公告)号：US20240344086A1

公开(公告)日：2024-10-17

申请号：US18701723

申请日：2022-10-19

申请人： AMGEN INC.

发明人： Christoph Adrian Kahl ,  Haejin Kim

IPC分类号： C12N15/86

CPC分类号： C12N15/86 ,  C12N2740/16022 ,  C12N2740/16043 ,  C12N2740/16052 ,  C12N2760/20243

摘要： Disclosed herein are lentiviral plasmid packaging compositions comprising unique mass ratios of four plasmids that are useful in producing lentiviral vectors. Also provided are methods of producing such lentiviral vectors by mixing a complexation solution comprising the lentiviral plasmid packaging composition with a transfection reagent and incubating the mixture for at least 10 minutes. transfecting a eukaryotic host cell with the lentiviral plasmid packaging composition, adding sodium butyrate to the transfected host cells about one day after transfection, and culturing the host cell. Exemplary embodiments of the method comprise a concentration of total plasmid in pg/mL of 0.25-3 and/or a mass ratio of total plasmid mass in pg to the mass of transfection reagent in pg extending from about 1:1 to about 1:3.

公开(公告)号：US20240200042A1

公开(公告)日：2024-06-20

申请号：US18598120

申请日：2024-03-07

申请人： ZHENHE PHARMACEUTICAL (HANGZHOU) CO., LTD.

发明人： GANG WANG ,  YIN YU ,  JIAN HUANG ,  HUALIN YI

IPC分类号： C12N9/12 ,  A61P9/00 ,  C07K14/005 ,  C07K14/435 ,  C07K14/47 ,  C07K14/55 ,  C12N9/22

CPC分类号： C12N9/127 ,  A61P9/00 ,  C07K14/005 ,  C07K14/435 ,  C07K14/43595 ,  C07K14/4715 ,  C07K14/55 ,  C12N9/22 ,  C12Y207/07048 ,  C12N2710/12022 ,  C12N2710/16622 ,  C12N2710/20022 ,  C12N2740/16022 ,  C12N2760/16122 ,  C12N2770/20022

摘要： The application relates to the technical field of biomedicine, in particular to a limited self-replicating mRNA molecular system, producing method and use. The limited self-replicating mRNA molecular system including: a first mRNA encoding a mutated alphavirus replicase; and at least one second mRNA encoding a target protein; by generating specific mutation adjustments in the nsP2 subunit of mutated replicase, this limited self-replicating mRNA molecular system can achieve limited self-replication and avoid cytotoxicity; by constructing different mRNA with mutated alphavirus replicase and different target proteins, the mutated alphavirus replicase encoded by the first mRNA can simultaneously replicate multiple different target proteins, achieving sustained expression of multiple target proteins.

公开(公告)号：US20190201342A1

公开(公告)日：2019-07-04

申请号：US16353303

申请日：2019-03-14

申请人： Her Majesty the Queen in Right of Canada as Represented by the Minister of Health

发明人： Ma Luo

IPC分类号： A61K9/14 ,  A61K39/21 ,  C07K14/74 ,  C07K14/005 ,  A61K39/12 ,  C07K14/16 ,  A61P31/18 ,  A61P37/04

CPC分类号： A61K9/14 ,  A61K39/12 ,  A61K39/21 ,  A61K2039/53 ,  A61K2039/54 ,  A61K2039/55555 ,  A61K2039/57 ,  A61P31/18 ,  A61P37/04 ,  C07K14/005 ,  C07K14/161 ,  C07K14/163 ,  C07K14/70539 ,  C12N2740/15034 ,  C12N2740/16022 ,  C12N2740/16034 ,  C12N2740/16222 ,  C12N2740/16322 ,  C12N2760/18043

摘要： Instead of generating immune responses to several HIV proteins and risk over activating more CD4+ T cells (easy targets for HIV-1 infection) as current candidate vaccines try to do, a lower magnitude, narrowly focused, well maintained virus specific CD8+ T cell response to multiple subtypes should destroy and eliminate a few founder viruses without inducing inflammatory responses that may activate more CD4+ T cells and provide more targets for HIV-1 virus infection. Specifically, described herein is a method that focuses the immune response to the 12 protease cleavage sites.

公开(公告)号：US10076567B2

公开(公告)日：2018-09-18

申请号：US15024600

申请日：2014-09-29

申请人： Duke University ,  Los Alamos National Security, LLC

发明人： Barton F. Haynes ,  Bette T. Korber ,  S. Munir Alam

IPC分类号： A61K39/21 ,  A61K38/16 ,  A61K38/21 ,  A61K9/127 ,  A61K9/00 ,  A61K39/12 ,  A61K47/48 ,  C07K14/005 ,  A61K39/39 ,  C12N7/00 ,  A61K39/00

CPC分类号： A61K39/21 ,  A61K9/0019 ,  A61K9/127 ,  A61K38/162 ,  A61K38/212 ,  A61K39/12 ,  A61K39/39 ,  A61K47/6911 ,  A61K2039/545 ,  A61K2039/55555 ,  A61K2039/55572 ,  A61K2039/575 ,  C07K14/005 ,  C12N7/00 ,  C12N2740/16022 ,  C12N2740/16034 ,  C12N2740/16122 ,  C12N2740/16134 ,  A61K2300/00

摘要： The present invention relates to peptides and compositions suitable for use in inducing anti-HIV-1 antibodies. The compositions comprise HIV-1 gp41 membrane proximal external region (MPER) peptide-liposome conjugates for induction of broadly reactive anti-HIV-1 antibodies. The invention also relates to methods of inducing neutralizing anti-HIV-1 antibodies using such compositions.

公开(公告)号：US09636396B2

公开(公告)日：2017-05-02

申请号：US13707885

申请日：2012-12-07

申请人： CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE ,  UNIVERSITE PARIS-SUD XI ,  INSTITUT GUSTAVE ROUSSY ,  VIROXIS S.A.S.

发明人： Thierry Heidmann

IPC分类号： A61K39/21 ,  C07K14/16 ,  C07K7/06 ,  C07K7/08 ,  C07K14/005 ,  A61K39/12

CPC分类号： A61K39/12 ,  A61K39/21 ,  C07K7/06 ,  C07K7/08 ,  C07K14/005 ,  C07K14/162 ,  C12N2740/15022 ,  C12N2740/15033 ,  C12N2740/15034 ,  C12N2740/16022 ,  C12N2740/16034 ,  C12N2740/16111 ,  C12N2740/16122 ,  C12N2740/16134

摘要： A pharmaceutical composition includes, as active substance a mutated lentiviral ENV protein, substantially devoid of immunosuppressive properties or a variant of the mutated lentiviral ENV protein or a fragment of the above proteins, in association with a pharmaceutically acceptable carrier.

公开(公告)号：US20170107585A1

公开(公告)日：2017-04-20

申请号：US15394085

申请日：2016-12-29

申请人： ZeptoMetrix Corporation

发明人： James C.D. Hengst ,  Gregory R. Chiklis

IPC分类号： C12Q1/70 ,  C12N7/00

CPC分类号： C12Q1/70 ,  C07K14/005 ,  C12N7/00 ,  C12N2730/10122 ,  C12N2730/10163 ,  C12N2740/15022 ,  C12N2740/16022 ,  C12N2740/16063 ,  C12N2740/16222 ,  C12N2770/24322 ,  C12N2770/24363 ,  C12Q1/6888 ,  C12Q1/689 ,  C12Q2600/166 ,  Y02A50/54 ,  Y02A50/59

摘要： The present invention discloses positive control material for nucleic acid amplification based detection of microorganisms in biological samples. The control material comprises purified microorganism that is rendered non-infectious but is amenable to nucleic acid amplification. Also disclosed is a process for making and using the control material.

公开(公告)号：US20170035877A1

公开(公告)日：2017-02-09

申请号：US14508369

申请日：2014-10-07

申请人： International AIDS Vaccine Initiative ,  The Scripps Research Institute

发明人： Richard Wyatt ,  Andrew Ward ,  Karen Tran ,  Shailendra Kumar ,  Jidnyasa Ingale ,  Javier Guenaga ,  Yu Feng ,  Viktoria Dubrowskaya ,  Natalia de Val Alta

IPC分类号： A61K39/21 ,  C07K14/005 ,  C12N7/00

CPC分类号： A61K39/21 ,  A61K39/12 ,  A61K2039/55505 ,  A61K2039/55555 ,  A61K2039/645 ,  C07K14/005 ,  C07K14/162 ,  C12N7/00 ,  C12N2740/16022 ,  C12N2740/16034 ,  C12N2740/16122 ,  C12N2740/16134

摘要： The present application relates to novel HIV-1 envelope glycoproteins which may be utilized as an HIV-1 vaccine immunogens, antigens for crystallization and for the identification of broad neutralizing antibodies. The present invention encompasses the preparation and purification of immunogenic compositions which are formulated into the vaccines of the present invention.

摘要翻译： 本申请涉及可用作HIV-1疫苗免疫原的新型HIV-1包膜糖蛋白，用于结晶的抗原和用于鉴定广泛的中和抗体。 本发明包括配制成本发明疫苗的免疫原性组合物的制备和纯化。

公开(公告)号：US20160136301A1

公开(公告)日：2016-05-19

申请号：US15005986

申请日：2016-01-25

申请人： CureVac AG

发明人： Florian VON DER MÜLBE ,  Ingmar Hoerr ,  Steve Pascolo

IPC分类号： A61K48/00 ,  A61K39/00 ,  C12N7/00 ,  A61K39/145 ,  A61K38/18

CPC分类号： A61K48/005 ,  A61K38/1735 ,  A61K38/1816 ,  A61K38/19 ,  A61K38/193 ,  A61K38/28 ,  A61K39/00 ,  A61K39/0011 ,  A61K39/0258 ,  A61K39/12 ,  A61K39/145 ,  A61K39/21 ,  A61K47/542 ,  A61K47/6455 ,  A61K48/00 ,  A61K48/0066 ,  A61K48/0075 ,  A61K48/0083 ,  A61K2039/53 ,  C07K14/005 ,  C07K14/245 ,  C07K14/4727 ,  C07K14/4748 ,  C12N7/00 ,  C12N15/11 ,  C12N15/67 ,  C12N2310/334 ,  C12N2310/336 ,  C12N2740/16022 ,  C12N2740/16034 ,  C12N2760/14122 ,  C12N2760/14134 ,  C12N2760/16022 ,  C12N2760/16034 ,  C12N2760/16071 ,  C12N2770/24122 ,  C12N2770/24134 ,  G16B20/00 ,  G16B30/00 ,  Y02A50/386 ,  Y02A50/388 ,  Y02A50/416 ,  Y02A50/464 ,  A61K2300/00

摘要： The present invention relates to a pharmaceutical composition comprising a modified mRNA that is stabilised by sequence modifications and optimised for translation. The pharmaceutical composition according to the invention is particularly well suited for use as an inoculating agent, as well as a therapeutic agent for tissue regeneration. In addition, a process is described for determining sequence modifications that promote stabilisation and translational efficiency of modified mRNA of the invention.

公开(公告)号：US20160130317A1

公开(公告)日：2016-05-12

申请号：US14983672

申请日：2015-12-30

申请人： UNIVERSITY HEALTH NETWORK

发明人： JEFFREY A. MEDIN ,  CHRISTOPHER J. PAIGE

IPC分类号： C07K14/54 ,  C12N15/86 ,  C12N7/00 ,  A61K48/00 ,  A61K39/00

CPC分类号： A61K35/545 ,  A61K38/208 ,  A61K39/0011 ,  A61K48/005 ,  A61K2039/515 ,  A61K2039/53 ,  A61K2039/585 ,  C07K14/5434 ,  C07K2319/00 ,  C12N7/00 ,  C12N15/86 ,  C12N2710/16122 ,  C12N2730/10122 ,  C12N2740/13043 ,  C12N2740/15043 ,  C12N2740/15071 ,  C12N2740/16022 ,  C12N2800/40 ,  C12N2830/48 ,  C12N2830/60

摘要： Compositions and methods for delivering immune modulatory molecules to result in a therapeutic effect are disclosed. The compositions and methods use stably integrating lentiviral delivery systems. The methods are useful for therapeutically and prophylactically treating cancer such as leukemia.

摘要翻译： 公开了用于递送免疫调节分子以产生治疗效果的组合物和方法。 组合物和方法使用稳定整合的慢病毒递送系统。 该方法可用于治疗和预防性治疗诸如白血病的癌症。

公开(公告)号：US20160101131A1

公开(公告)日：2016-04-14

申请号：US14968889

申请日：2015-12-14

申请人： AIMSCO Limited

发明人： Bryan Youl

IPC分类号： A61K35/16 ,  A61K9/00

CPC分类号： A61K35/16 ,  A61K9/0021 ,  A61K39/39516 ,  C07K14/005 ,  C07K16/06 ,  C07K16/10 ,  C07K16/2833 ,  C12N2740/16022

摘要： Provided are methods for the treatment of various neural disorders including non-demyelinating neural disorders, such as Alzheimer's disease, as well as methods for the treatment of various autoimmune or immune-mediated disorders, such as scleroderma. Also provided are methods for restoring or improving one or more nerve functions, such as neural transmission, in a human with a neural disorder, such as a non-demyelinating neural disorder. Each of these methods comprise the administration of a serum composition obtained from a goat after challenge with an immunogen, in particular HIV or a lysate thereof.

摘要翻译： 提供了用于治疗各种神经障碍的方法，包括非脱髓鞘性神经障碍，例如阿尔茨海默病，以及治疗各种自身免疫或免疫介导的疾病如硬皮病的方法。 还提供了用于在具有神经障碍（例如非脱髓鞘性神经障碍）的人中恢复或改善一种或多种神经功能（例如神经传递）的方法。 这些方法中的每一种包括在用免疫原特别是HIV或其裂解物攻击后从山羊获得的血清组合物的施用。